ARCHIVE

• REGULATORY NEWS IN BRIEF
  May 19, 2003

• Korosho's Project Team Calls For Measures Regarding Insulin Preparations
  May 12, 2003

• Mie Prefecture to Establish Clinical Trial Network
  May 12, 2003

• MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
  May 12, 2003

• BULLETIN
  May 12, 2003

• Yamanouchi's 1st Genomic Drug to Enter Clinical Stage in 2005
  May 12, 2003

• Disagreement on Merger Ratio Ends Merger Plan of Teijin, Kyorin
  May 12, 2003

• Two Business Plans Selected in 3rd Bio-business Competition
  May 12, 2003

• PAL Amendments as Related to GMP Explained by Korosho Official
  May 12, 2003

• Legal Basis for Regenerative Medicine Regulations Proposed by JHSF
  May 12, 2003

• Allergan Launches Kyorin's Gatifloxacin Ophthalmic Solution in US
  May 12, 2003

• PRESS SEMINAR
  May 12, 2003

• Fujisawa: Sales Increase for 4 Consecutive Years
  May 12, 2003

• RESEARCH & DEVELOPMENT NEWS IN BRIEF
  May 12, 2003

• NEW PRODUCTS
  May 12, 2003

• OTC NEWS IN BRIEF
  May 12, 2003

• IMCJ Designated for Treatment of Specific Infectious Diseases
  May 12, 2003

• MEDICAL DEVICE NEWS IN BRIEF
  May 12, 2003

• Ribavirin Not Recommended for SARS at Present: Korosho Expert WG
  May 12, 2003

• DIAGNOSTIC NEWS IN BRIEF
  May 12, 2003

ページ

• « 先頭
• ‹ Prev
• …
• 600
• 601
• 602
• 603
• 604
• 605
• 606
• 607
• 608
• …
• Next ›
• 最終 »